Kakabadze Zurab, Kipshidze Nicholas, Paresishvili Teona, Kipshidze Nodar, Vadachkoria Zurab, Chakhunashvili David
Department of Clinical Anatomy, Tbilisi State Medical University, Tbilisi 0186, Georgia.
Department of Interventional Cardiology, NY Cardiovascular Research, New York, NY 10019, USA.
Stem Cells Int. 2022 Jun 22;2022:8418509. doi: 10.1155/2022/8418509. eCollection 2022.
The acute respiratory distress syndrome (ARDS) is one of the main causes of high mortality in patients with coronavirus (COVID-19). In recent years, due to the coronavirus pandemic, the number of patients with ARDS has increased significantly. Unfortunately, until now, there are no effective treatments for ARDS caused by COVID-19. Many drugs are either ineffective or have a low effect. Currently, there have been reports of efficient use of mesenchymal stem cells (MSCs) for the treatment of ARDS caused by COVID-19. We investigated the influence of freeze-dried human placenta-derived mesenchymal stem cells (HPMSCs) in ARDS rat model. All animals have received intratracheal injection of 6 mg/kg of lipopolysaccharide (LPS). The rats were randomly divided into five groups: I: LPS, II: LPS+dexamethasone, III: LPS+HPMSCs, IV: HPMSC, and V: saline. ARDS observation time was short-term and amounted to 168 hours. The study has shown that HPMSCs are able to migrate and attach to damaged lung tissue, contributing to the resolution of pathology, restoration of function, and tissue repair in the alveolar space. Studies have also shown that the administration of HPMSCs in animals with ARDS model significantly reduced the levels of key cytokines such as IL-1, IL-6, and TNF-. Freeze-dried placental stem cell is a very promising biomaterial for the treatment of ARDS. The human placenta can be easily obtained because it is considered as a medical waste. At the same time, a huge number of MSCs can be obtained from the placental tissue, and there is no ethical controversy around their use. The freeze-dried MSCs from human placental tissue can be stored sterile at room temperature for a long time before use.
急性呼吸窘迫综合征（ARDS）是冠状病毒病（COVID-19）患者高死亡率的主要原因之一。近年来，由于冠状病毒大流行，ARDS患者数量显著增加。不幸的是，迄今为止，尚无针对COVID-19所致ARDS的有效治疗方法。许多药物要么无效，要么疗效不佳。目前，已有关于有效利用间充质干细胞（MSCs）治疗COVID-19所致ARDS的报道。我们研究了冻干人胎盘来源的间充质干细胞（HPMSCs）对ARDS大鼠模型的影响。所有动物均经气管内注射6 mg/kg脂多糖（LPS）。大鼠被随机分为五组：I：LPS组；II：LPS+地塞米松组；III：LPS+HPMSCs组；IV：HPMSCs组；V：生理盐水组。ARDS观察期为短期，共168小时。研究表明，HPMSCs能够迁移并附着于受损肺组织，有助于病理状态的消退、功能恢复以及肺泡腔内组织修复。研究还表明，在ARDS模型动物中给予HPMSCs可显著降低关键细胞因子如IL-1、IL-6和TNF-的水平。冻干胎盘干细胞是治疗ARDS非常有前景的生物材料。人胎盘易于获取，因为它被视为医疗废弃物。同时，可从胎盘组织中获得大量MSCs，且其使用不存在伦理争议。来自人胎盘组织的冻干MSCs在使用前可在室温下无菌储存很长时间。
